Prostate Cancer
Conditions
Brief summary
French epidemiological data have shown a heterogeneous distribution of the risk of mortality from prostate cancer according to region. The main objective is to describe the distribution of prostate cancer stages when first line hormonal therapy is introduced (overall and by region).
Interventions
DRUGDegarelix or GnRH agonist
Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice
Sponsors
Ferring Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with histologically demonstrated prostatic adenocarcinoma. * Patients never previously treated with hormonal therapy for prostate cancer. * Patients eligible for hormonal therapy after initial consultation (alone or in combination with curative treatment). * Patients agreeing to the collection of personal health data for the purposes of the study. * Patients with locally advanced or metastatic prostatic cancer tumours or a biological recurrence after curative treatment.
Exclusion criteria
* Patients participating in a clinical study involving prostate cancer at the time of inclusion in the investigation. * Patients having received or currently receiving hormonal treatment for prostate cancer (surgical castration or other hormonal manipulation, including GnRH receptor antagonists, antiandrogens, oestrogens, 5 alpha reductase inhibitors).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Estimated percentage of different prostate cancer stages (overall and by region) | During a single consultation when first-line prostate cancer hormone therapy is started | The stages of prostate cancer are classified as locally advanced, metastatic and biological recurrence. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The characteristics of the patients with prostate cancer by region | During a single consultation when first-line prostate cancer hormone therapy is started | Characteristics are described by demography, tumour characteristics, Gleason score, D'Amico score, prostate specific antigen (PSA), Testosterone and treatment history |
| The influence of regional factors on staging of prostate cancer | During a single consultation when first-line prostate cancer hormone therapy is started | The regional influence will be demonstrated by modelling the probability of a patient being at one of the cancer stages (locally advanced cancer, metastatic cancer, biological recurrence). |
Countries
France
Outcome results
None listed